ANZCTR search results

Research Aims: To test the effect of a patient reward system (Instant scratchie lottery ticket) or augmented education improves: a) quality of bowel preparations b) and the polyp detection rate To test whether the total SAGIS score correlates with the number of polyps found Research Design & Methods to Achieve Aims: During one calendar year 300 outpatients referred for a colonoscopy will be recruited who have consented to the study. The quality of bowel preparation will be scored via the Boston bowel preparation scale, which is the most extensively validated scoring system. Block randomisation will be used to allocate all patients consented on a given day into one of three treatment groups (Scratchie ticket lottery ticket reward vs. no reward vs. intensified education).

The study drug AB-729 is being developed as a potential new treatment for Chronic Hepatitis B (CHB). The main goal of the study is to determine whether AB-729 is safe and well tolerated when given at different doses. We will also measure the levels of the drug in the blood at different times. The study will be conducted in 3 parts. Part 2 will be an open-label, non-randomized, SAD design and will be conducted in up to 30 subjects with CHB infection.

Transcranial magnetic stimulation is a safe and well proven technique used to treat a number of psychiatric and neurological disorders. It has never been trialled in MS. We have demonstrated that TMS may have an effect on the ability of brain cells to replenish the myelin sheath (the insulation surrounding nerve cells) which may thus help multiple sclerosis lesions to heal. This data is from animals and cell culture and has not been shown in humans. This study is a safety/tolerability study of TMS in humans to determine whether wee can give TMS to people with MS with acceptable tolerability and safety. We will also collect preliminary data on the effects of TMS on people with MS and their MRI scans

The aim of the current study is to conduct a non-randomised three-arm parallel controlled clinical trial comparing the cognitive, emotional, and functional outcomes of acute ischaemic stroke patients treated with ECR and t-PA, as well as those who receive no treatment (neither ECR nor t-PA) in the acute phase.

Incidence of venous thromboembolism (VTE) in adult nephrotic syndorme is 25-30% and this risk is inversely related to serum albumin (protein) level. This study will investigate whether apixaban (new oral anticoagulant) is as effective as warfarin which is prescribed routinely when patients serum albumin level is very low. Measurement of apixaban in this study will give a good insight into pharmacokinetic of the drug in nephrotic syndrome.

We plan to determine if narrow (targeted) spectrum antibiotics have the same outcomes as broad spectrum antibiotics when treating mild or moderate diabetic foot infections. We know through research that often diabetic foot infections have two main bacteria present, and more often than not, these infections can be treated with a narrow targeted spectrum antibiotic.

An emerging body of research has shown promising effects of exercise-based injury prevention programs (IPPs) in reducing knee injury risk. However, the efficacy of IPPs as reflected in clinical trials have not been replicated in real-world practice largely due to lack of compliance and implementation support. Individualized IPPs targeted to specific biomechanical components may provide the most prudent and effectual implementation strategy by specifically targeting high risk groups. However, the individualization process is hampered by the absence of field-based objective screening methods to stratify risk according to trunk dominance deficits, and a lack of consensus on the ‘best’ combination of IPP components. Thus, the objectives of this study are 1) to identify the best combination of field-based tests to screen for trunk dominance deficits, and 2) to explore the effects of an injury prevention program individualized according to trunk dominance screening results in reducing knee injury risk in athletes. Study hypotheses: 1) that field-based tests for trunk dominance deficits are a valid and reliable alternative compared to three-dimensional biomechanical motion analysis; 2) that individualization of IPPs are more effective in decreasing trunk dominance deficits than generic IPPs

Whist palliative care is highly effective for patients with dementia and their carers it is rarely accessed. We hypothesize that the provision of education, advance care planning and better referral to palliative care for carers will reduce the number of people with dementia that die in hospital and result in improvements in systems and patients centered outcomes. Therefore, this research is about increasing access to palliative care for a group of patients that are currently underrepresented.

This study aims to evaluate whether stereotactic ablative radiotherapy (SABR) is a reasonable and safe treatment option for patients with non-small cell lung cancer (NSCLC) where their cancer is large and/or has also spread to the nearby lymph nodes. Who is it for? You may be eligible to join this study if you are aged 18 or older with a diagnosis of stage III or IV non-small cell lung carcinoma and ineligible for standard of care concurrent chemo-radiotherapy. Study details Participants in this study will undergo stereotactic ablative radiotherapy (SABR). SABR is a specialised form of radiotherapy whereby large doses of radiation are given in fewer treatments. Participants will attend between 6-12 SABR sessions across 2-3 weeks, and will then be followed up regularly post radiotherapy, in order to evaluate treatment safety, quality of life, tumour response and survival. It is hoped this research will contribute to the field of oncology and improve the health outcomes of patients with lung cancer.

This study will determine if the use of adavosertib (cohort 1 & 2) or ceralasertib (cohort 3) as monotherapy provides clinical benefit to patients with high grade serous ovarian cancer Who is it for? You may be eligible to join this study if you are aged 18 and above and have platinum resistant high grade serous ovarian cancer with Cyclin E1 over-expression Study details Participants in this study are now being enrolled into an additional third cohort. Cohort 1 and 2 enrolled 71 participants with Cyclin E1 over-expression (Non-amplified or Amplified). who received the same intervention: daily oral adavosertib tablet from Day 1-5 and Day 8-12 of a 21-day cycle for a maximum of 24 months. Cohort 3 plans to enrol 32 participants with Cyclin E1 over-expression (Non-amplified or Amplified). Participants will receive twice daily oral ceralasertib tablets from day 1-14 of a 28 day cycle for a maximum of 24 months. Patients will undergo 4-weekly appointments for their treatment duration, have bloods taken for translational research and may also be required to have a biopsy performed after the end of their first cycle. All participants will be monitored regularly in order to assess clinical response and treatment safety. It is hoped that IGNITE will provide clinical benefit to patients with high grade serous ovarian cancer who have Cyclin E1 expression and will be able to provide a new treatment option for patients with this genetic fault.